ER

Menarini, Oxford BioTherapeutics to collaborate on portfolio of antibody-based cancer drugs

Tuesday, October 30, 2012 11:52 AM

Menarini Group, an international pharmaceutical company based in Italy, and Oxford BioTherapeutics (OBT), an international biotechnology company based in the U.K., have formed a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »

Patheon to acquire Banner Pharmacaps

Tuesday, October 30, 2012 10:24 AM

Patheon, a Durham, N.C.-based provider of contract development and manufacturing services, has signed a definitive agreement with Vion, a global manufacturer of foodstuffs and ingredients based in the Netherlands, to acquire Banner Pharmacaps, a High Point, N.C.-based specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

More... »

CRA Holdings acquires Radiant Research

Friday, October 26, 2012 03:16 PM

Kinderhook Industries has announced the acquisition of Radiant Research by CRA Holdings, one of its portfolio companies. The deal represents the eighth healthcare services transaction completed by Kinderhook. Financial terms of the transaction were not disclosed.

More... »

Amgen, KPCB partner to create new spin-out biotech

Friday, October 26, 2012 02:43 PM

Amgen, a biotech based in Thousand Oaks, Calif., and Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm, have created Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology.

More... »

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

More... »

Prezista receives E.C. approval for young children with HIV-1 infection

Friday, October 26, 2012 10:46 AM

The European Commission (E.C.) has approved Janssen/Cilag International’s 100mg/ml oral suspension of Prezista (darunavir), and the use of darunavir co-administered with low dose ritonavir, for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART)-experienced pediatric patients age three and above, weighing at least 15kg. The drug must be taken in combination with other ARTs.

More... »

Synteract upgrades safety database systems to Oracle Argus

Friday, October 26, 2012 10:24 AM

Synteract, a full service CRO based in Carlsbad, Calif., has implemented two Oracle Argus 7.0 modules to its pharmacovigilance technology platform, Oracle Argus Safety and Oracle Argus Interchange.

More... »